Issues

The cover figure, which has been truncated, illustrates the results of unsupervised hierarchical clustering of gene-expression profiles of 86 out of the original 126 breast tumors for which there was residual disease after neoadjuvant chemotherapy. The clustering identified patients with an enhanced risk of recurrence who, predominantly, had disease that was ER-negative and/or highly proliferative (as evidenced by high Ki67). The first column from the left indicates the presence of recurrence; the second column, ER-positivity; the third column, HER2-positivity; and the last column, residual Ki67, ranging from 0 to 100%. For details, see the complete figure in the article by Klintman and colleagues on page 2405 of this issue.